2021 Q4 Form 10-Q Financial Statement
#000155837021014076 Filed on November 02, 2021
Income Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
Revenue | $20.41M | $21.54M | $18.39M |
YoY Change | 10.62% | 17.15% | -11.83% |
Cost Of Revenue | $487.0K | $151.0K | $140.0K |
YoY Change | 52.19% | 7.86% | -54.84% |
Gross Profit | $19.92M | $21.39M | $16.15M |
YoY Change | 14.28% | 32.47% | 41.58% |
Gross Profit Margin | 97.61% | 99.3% | 87.82% |
Selling, General & Admin | $24.52M | $22.88M | $17.43M |
YoY Change | 12.35% | 31.25% | -3.81% |
% of Gross Profit | 123.05% | 106.94% | 107.93% |
Research & Development | $13.30M | $18.30M | $14.60M |
YoY Change | -12.13% | 25.34% | 0.95% |
% of Gross Profit | 66.78% | 85.55% | 90.41% |
Depreciation & Amortization | $404.0K | $261.0K | $160.0K |
YoY Change | 92.38% | 63.13% | 0.0% |
% of Gross Profit | 2.03% | 1.22% | 0.99% |
Operating Expenses | $37.82M | $41.18M | $32.03M |
YoY Change | 2.32% | 28.56% | -1.7% |
Operating Profit | -$17.90M | -$19.79M | -$13.78M |
YoY Change | -8.35% | 43.57% | 14.49% |
Interest Expense | -$1.283M | $1.317M | $429.0K |
YoY Change | 212.93% | 206.99% | 5262.5% |
% of Operating Profit | |||
Other Income/Expense, Net | |||
YoY Change | |||
Pretax Income | -$22.70M | -$21.09M | -$14.17M |
YoY Change | 17.99% | 48.78% | 23.36% |
Income Tax | -$60.00K | -$136.0K | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$22.64M | -$20.95M | -$14.17M |
YoY Change | 17.68% | 47.82% | 23.36% |
Net Earnings / Revenue | -110.94% | -97.26% | -77.08% |
Basic Earnings Per Share | -$0.12 | -$0.08 | |
Diluted Earnings Per Share | -$132.3K | -$0.12 | -$0.08 |
COMMON SHARES | |||
Basic Shares Outstanding | 171.0M | 170.9M | 168.9M |
Diluted Shares Outstanding | 170.9M | 168.9M |
Balance Sheet
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $125.0M | $143.1M | $72.80M |
YoY Change | 118.09% | 96.63% | -32.28% |
Cash & Equivalents | $18.89M | $30.40M | $36.57M |
Short-Term Investments | $106.1M | $112.7M | $36.20M |
Other Short-Term Assets | $7.412M | $5.932M | $10.40M |
YoY Change | -47.06% | -42.96% | 79.31% |
Inventory | $6.616M | $7.035M | $2.050M |
Prepaid Expenses | |||
Receivables | $15.47M | $14.99M | $14.63M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $154.5M | $171.1M | $99.85M |
YoY Change | 73.59% | 71.36% | -20.76% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $2.184M | $2.655M | $2.517M |
YoY Change | -18.39% | 5.48% | -91.44% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $974.0K | $935.0K | $820.0K |
YoY Change | 18.2% | 14.02% | 17.14% |
Total Long-Term Assets | $12.86M | $15.41M | $23.21M |
YoY Change | -39.89% | -33.59% | -22.89% |
TOTAL ASSETS | |||
Total Short-Term Assets | $154.5M | $171.1M | $99.85M |
Total Long-Term Assets | $12.86M | $15.41M | $23.21M |
Total Assets | $167.3M | $186.5M | $123.1M |
YoY Change | 51.6% | 51.57% | -21.17% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $3.795M | $3.144M | $2.283M |
YoY Change | 2.37% | 37.71% | -15.44% |
Accrued Expenses | $3.580M | $42.00M | $28.80M |
YoY Change | -2.21% | 45.82% | 7.46% |
Deferred Revenue | $2.596M | $3.157M | $3.069M |
YoY Change | -13.98% | 2.87% | |
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $63.55M | $59.28M | $34.19M |
YoY Change | 55.61% | 73.38% | 10.3% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $19.91M | $19.89M | $19.80M |
YoY Change | 0.58% | 0.44% | 102.04% |
Other Long-Term Liabilities | $52.73M | $54.37M | $5.000M |
YoY Change | 945.13% | 987.3% | -89.22% |
Total Long-Term Liabilities | $52.73M | $54.37M | $5.000M |
YoY Change | 945.13% | 987.3% | -91.1% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $63.55M | $59.28M | $34.19M |
Total Long-Term Liabilities | $52.73M | $54.37M | $5.000M |
Total Liabilities | $116.3M | $113.6M | $39.19M |
YoY Change | 153.41% | 189.97% | -55.06% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$1.324B | -$1.301B | -$1.287B |
YoY Change | 1.37% | 1.13% | |
Common Stock | $1.354B | $1.351B | $1.338B |
YoY Change | 1.07% | 0.99% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $30.37M | $49.67M | $50.96M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $167.3M | $186.5M | $123.1M |
YoY Change | 51.6% | 51.57% | -21.17% |
Cashflow Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$22.64M | -$20.95M | -$14.17M |
YoY Change | 17.68% | 47.82% | 23.36% |
Depreciation, Depletion And Amortization | $404.0K | $261.0K | $160.0K |
YoY Change | 92.38% | 63.13% | 0.0% |
Cash From Operating Activities | -$19.09M | -$10.30M | -$19.48M |
YoY Change | 22.5% | -47.14% | 33.06% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $21.00K | -$170.0K | -$200.0K |
YoY Change | -104.2% | -15.0% | -42.86% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $6.467M | -$44.23M | $19.72M |
YoY Change | -29.86% | -324.27% | 39340.0% |
Cash From Investing Activities | $6.488M | -$44.40M | $19.53M |
YoY Change | -25.51% | -327.33% | -6834.48% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 1.085M | 274.0K | 50.00K |
YoY Change | 61.94% | 448.0% | -99.49% |
NET CHANGE | |||
Cash From Operating Activities | -19.09M | -10.30M | -19.48M |
Cash From Investing Activities | 6.488M | -44.40M | 19.53M |
Cash From Financing Activities | 1.085M | 274.0K | 50.00K |
Net Change In Cash | -11.51M | -54.42M | 100.0K |
YoY Change | 85.69% | -54520.0% | -101.95% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$19.09M | -$10.30M | -$19.48M |
Capital Expenditures | $21.00K | -$170.0K | -$200.0K |
Free Cash Flow | -$19.11M | -$10.13M | -$19.28M |
YoY Change | 26.7% | -47.47% | 34.92% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2021Q3 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
|
0 | |
CY2021Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
dei |
Trading Symbol
TradingSymbol
|
RIGL | ||
CY2021Q3 | rigl |
Net Sublease Income Expense
NetSubleaseIncomeExpense
|
||
CY2020Q3 | rigl |
Net Sublease Income Expense
NetSubleaseIncomeExpense
|
||
rigl |
Net Sublease Income Expense
NetSubleaseIncomeExpense
|
|||
rigl |
Net Sublease Income Expense
NetSubleaseIncomeExpense
|
|||
dei |
Entity Registrant Name
EntityRegistrantName
|
RIGEL PHARMACEUTICALS INC | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001034842 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
0-29889 | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
94-3248524 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1180 Veterans Blvd. | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
South San Francisco | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94080 | ||
dei |
City Area Code
CityAreaCode
|
650 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
624-1100 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.001 per share | ||
CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
171006061 | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30403000 | |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30373000 | |
CY2021Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
112743000 | |
CY2020Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26954000 | |
CY2021Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
14991000 | |
CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15973000 | |
CY2021Q3 | us-gaap |
Inventory Net
InventoryNet
|
7035000 | |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
1638000 | |
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5932000 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
14045000 | |
CY2021Q3 | us-gaap |
Assets Current
AssetsCurrent
|
171104000 | |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
88983000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2655000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2676000 | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
11824000 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17895000 | |
CY2021Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
935000 | |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
824000 | |
CY2021Q3 | us-gaap |
Assets
Assets
|
186518000 | |
CY2020Q4 | us-gaap |
Assets
Assets
|
110378000 | |
CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3144000 | |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3707000 | |
CY2021Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9461000 | |
CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9592000 | |
CY2021Q3 | rigl |
Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
|
9475000 | |
CY2020Q4 | rigl |
Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
|
4889000 | |
CY2021Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
13486000 | |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
11014000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
9574000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8621000 | |
CY2021Q3 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
3157000 | |
CY2020Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
3018000 | |
CY2021Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
10985000 | |
CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
59282000 | |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
40841000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3314000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10651000 | |
CY2021Q3 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
19887000 | |
CY2020Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
19815000 | |
CY2021Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
54365000 | |
CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
5045000 | |
CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
171000 | |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
169000 | |
CY2021Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1350736000 | |
CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
1339833000 | |
CY2021Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
8000 | |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-4000 | |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1301245000 | |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1305972000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49670000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34026000 | |
CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
186518000 | |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
110378000 | |
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
21543000 | |
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18389000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
128827000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
90171000 | ||
CY2021Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
151000 | |
CY2020Q3 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
140000 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
596000 | ||
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
574000 | ||
CY2021Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
18300000 | |
CY2020Q3 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
14600000 | |
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
51933000 | ||
us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
44963000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
563000 | ||
CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
1317000 | |
CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
429000 | |
CY2021Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
22877000 | |
CY2020Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
17430000 | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
67376000 | ||
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
54780000 | ||
CY2021Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
41328000 | |
CY2020Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
32170000 | |
us-gaap |
Costs And Expenses
CostsAndExpenses
|
119905000 | ||
us-gaap |
Costs And Expenses
CostsAndExpenses
|
100317000 | ||
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19785000 | |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13781000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
8922000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10146000 | ||
CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
14000 | |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
36000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
31000 | ||
us-gaap |
Interest Expense
InterestExpense
|
3561000 | ||
us-gaap |
Interest Expense
InterestExpense
|
924000 | ||
CY2021Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-21088000 | |
CY2020Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-14174000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
5392000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10507000 | ||
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-136000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
665000 | ||
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20952000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14174000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
4727000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-10507000 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.12 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.08 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.03 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.06 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.12 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.08 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.03 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.06 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
170886000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
168932000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
170297000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
168658000 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
170886000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
168932000 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
176452000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
168658000 | ||
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-20952000 | |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14174000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
4727000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10507000 | ||
CY2021Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1000 | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-44000 | |
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
12000 | ||
us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-21000 | ||
CY2021Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20951000 | |
CY2020Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14218000 | |
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
4739000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10528000 | ||
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
34026000 | |
CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
39500000 | |
CY2021Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
3000 | |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
2097000 | |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2672000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
78298000 | |
CY2021Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-13821000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
8000 | |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1319000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2306000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68110000 | |
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-20952000 | |
CY2021Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1000 | |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
274000 | |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2237000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
49670000 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
53815000 | |
CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
21243000 | |
CY2020Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
55000 | |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1336000 | |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2050000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
78499000 | |
CY2020Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17576000 | |
CY2020Q2 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-32000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
541000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1778000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
63210000 | |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14174000 | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-44000 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
52000 | |
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1911000 | |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
50955000 | |
us-gaap |
Profit Loss
ProfitLoss
|
4727000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-10507000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7147000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5665000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
758000 | ||
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
500000 | ||
rigl |
Noncash Interest Expense
NoncashInterestExpense
|
2314000 | ||
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-171000 | ||
us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
171000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-982000 | ||
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4520000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
5325000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
235000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-8113000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
893000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
111000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
124000 | ||
rigl |
Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
|
6071000 | ||
rigl |
Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
|
5836000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-656000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1869000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-131000 | ||
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-646000 | ||
rigl |
Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
|
4586000 | ||
rigl |
Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
|
-2664000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
2563000 | ||
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
1731000 | ||
rigl |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-6384000 | ||
rigl |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-5239000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
139000 | ||
us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-23477000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
24964000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-36613000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
117076000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
63671000 | ||
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
31200000 | ||
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
103184000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
648000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
758000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-86524000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
38755000 | ||
rigl |
Cost Share Advance From Collaboration Partner
CostShareAdvanceFromCollaborationPartner
|
57900000 | ||
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
3690000 | ||
us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1929000 | ||
us-gaap |
Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
|
9975000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
61590000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
11904000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
30000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
14046000 | ||
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30373000 | |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22521000 | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30403000 | |
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
36567000 | |
us-gaap |
Interest Paid Net
InterestPaidNet
|
1094000 | ||
us-gaap |
Interest Paid Net
InterestPaidNet
|
814000 | ||
us-gaap |
Nature Of Operations
NatureOfOperations
|
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Nature of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We are a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our first product approved by the United States Food and Drug Administration (FDA) is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the United Kingdom (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Fostamatinib is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (wAIHA); a Phase 3 clinical trial for the treatment of hospitalized high-risk patients with COVID-19; a National Institute of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) sponsored Phase 3 trial (ACTIV-4 Host Tissue Trial) for the treatment of COVID-19 in hospitalized patients; and a Phase 2 trial for the treatment of COVID-19 being conducted by Imperial College London. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our other clinical programs include our interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly). In addition, we have product candidates in clinical development with partners AstraZeneca AB (AZ), BerGenBio ASA (BerGenBio) and Daiichi Sankyo (Daiichi). </p> | ||
CY2021Q3 | rigl |
Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
|
100000 | |
CY2020Q4 | rigl |
Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
|
171000 | |
us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:9pt;margin-top:9pt;"><b style="font-size:10pt;font-weight:bold;">Basis of Presentation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP), for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Act of 1933, as amended (Securities Act). Accordingly, they do not include all the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments that we believe are necessary to fairly state our financial position and the results of our operations and cash flows. Interim-period results are not necessarily indicative of results of operations or cash flows for a full-year or any subsequent interim period. The balance sheet as of December 31, 2020 has been derived from audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because certain disclosures required by U.S. GAAP for complete financial statements are not included herein, these interim unaudited condensed financial statements and the notes accompanying them should be read in conjunction with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p> | ||
CY2021Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-20952000 | |
CY2020Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14174000 | |
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
4727000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-10507000 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
170886000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
168932000 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
170297000 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
168658000 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
170886000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
168932000 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
170297000 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
168658000 | ||
us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
6155000 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
170886000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
168932000 | |
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
176452000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
168658000 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.12 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.08 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.03 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.06 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.12 | |
CY2020Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.08 | |
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.03 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.06 | ||
CY2021Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
31037000 | |
CY2020Q3 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
27705000 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9454000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
27705000 | ||
rigl |
Share Based Compensation Number Of Stock Option Plans
ShareBasedCompensationNumberOfStockOptionPlans
|
2 | ||
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2202000 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1884000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
7147000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5665000 | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
10403690 | |
CY2021Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
21543000 | |
CY2020Q3 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
18389000 | |
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
128827000 | ||
us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
90171000 | ||
CY2020Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
6065000 | |
us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
12060000 | ||
CY2021Q3 | us-gaap |
Accretion Expense
AccretionExpense
|
836000 | |
us-gaap |
Accretion Expense
AccretionExpense
|
1900000 | ||
CY2020Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
449000 | |
CY2021Q3 | us-gaap |
Inventory Net
InventoryNet
|
7035000 | |
us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
10827000 | ||
CY2021Q3 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
7298000 | |
CY2019Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
3332000 | |
us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
9076000 | ||
us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
7499000 | ||
CY2020Q3 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
4909000 | |
rigl |
Sales Discounts And Allowances
SalesDiscountsAndAllowances
|
13300000 | ||
CY2021Q3 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
7300000 | |
rigl |
Sales Discounts And Allowances
SalesDiscountsAndAllowances
|
10100000 | ||
rigl |
Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
|
125000000.0 | ||
CY2021Q3 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
5142000 | |
CY2021Q3 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
483000 | |
CY2020Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1189000 | |
CY2021Q3 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1410000 | |
CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
1638000 | |
CY2020Q4 | us-gaap |
Advances On Inventory Purchases
AdvancesOnInventoryPurchases
|
4000000.0 | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
11800000 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17900000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
143146000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
57327000 | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30403000 | |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
30373000 | |
CY2021Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
112743000 | |
CY2020Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26954000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
143146000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
57327000 | |
CY2021Q3 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
114734000 | |
CY2021Q3 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
114742000 | |
CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
35856000 | |
CY2020Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
35852000 | |
rigl |
Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
|
P227D | ||
CY2020 | rigl |
Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
|
P78D | |
CY2021Q3 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
19 | |
us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
|
0 | ||
CY2021Q3 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
38488000 | |
CY2021Q3 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
7000 | |
rigl |
Lessee Leasing Arrangements Operating Leases Number Of Renewal Term Periods
LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTermPeriods
|
2 | ||
CY2021Q3 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
CY2014Q4 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
57000 | |
CY2017Q3 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
9328 | |
CY2021Q3 | rigl |
Expected Income From Sublease
ExpectedIncomeFromSublease
|
6200000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
12900000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
19300000 | |
CY2021Q3 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y3M29D | |
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1340000 | |
CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1340000 | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
4020000 | ||
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
4020000 | ||
CY2021Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
259000 | |
CY2020Q3 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
237000 | |
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
651000 | ||
us-gaap |
Variable Lease Cost
VariableLeaseCost
|
704000 | ||
CY2021Q3 | us-gaap |
Lease Cost
LeaseCost
|
1599000 | |
CY2020Q3 | us-gaap |
Lease Cost
LeaseCost
|
1577000 | |
us-gaap |
Lease Cost
LeaseCost
|
4671000 | ||
us-gaap |
Lease Cost
LeaseCost
|
4724000 | ||
CY2021Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2529000 | |
CY2020Q3 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2431000 | |
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7554000 | ||
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
7263000 | ||
CY2021Q3 | rigl |
Fixed Sublease Expense
FixedSubleaseExpense
|
1095000 | |
CY2020Q3 | rigl |
Fixed Sublease Expense
FixedSubleaseExpense
|
1096000 | |
rigl |
Fixed Sublease Expense
FixedSubleaseExpense
|
3285000 | ||
rigl |
Fixed Sublease Expense
FixedSubleaseExpense
|
3286000 | ||
CY2021Q3 | rigl |
Variable Sublease Expense
VariableSubleaseExpense
|
236000 | |
CY2020Q3 | rigl |
Variable Sublease Expense
VariableSubleaseExpense
|
245000 | |
rigl |
Variable Sublease Expense
VariableSubleaseExpense
|
680000 | ||
rigl |
Variable Sublease Expense
VariableSubleaseExpense
|
742000 | ||
CY2021Q3 | us-gaap |
Sublease Income
SubleaseIncome
|
1331000 | |
CY2020Q3 | us-gaap |
Sublease Income
SubleaseIncome
|
1341000 | |
us-gaap |
Sublease Income
SubleaseIncome
|
3965000 | ||
CY2021Q3 | rigl |
Lessee Operating Lease Liability Net Payments Due Year Two
LesseeOperatingLeaseLiabilityNetPaymentsDueYearTwo
|
483000 | |
us-gaap |
Sublease Income
SubleaseIncome
|
4028000 | ||
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2529000 | |
CY2021Q3 | rigl |
Sublease Payments To Be Received Remainder Of Fiscal Year
SubleasePaymentsToBeReceivedRemainderOfFiscalYear
|
1137000 | |
CY2021Q3 | rigl |
Lessee Operating Lease Liability Net Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityNetPaymentsRemainderOfFiscalYear
|
1392000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
10485000 | |
CY2021Q3 | rigl |
Sublease Payments To Be Received Next Twelve Months
SubleasePaymentsToBeReceivedNextTwelveMonths
|
4716000 | |
CY2021Q3 | rigl |
Lessee Operating Lease Liability Net Payments Next Twelve Months
LesseeOperatingLeaseLiabilityNetPaymentsNextTwelveMonths
|
5769000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
877000 | |
CY2021Q3 | rigl |
Sublease Payments To Be Received Two Years
SubleasePaymentsToBeReceivedTwoYears
|
394000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
13891000 | |
CY2021Q3 | rigl |
Sublease Payments To Be Received
SubleasePaymentsToBeReceived
|
6247000 | |
CY2021Q3 | rigl |
Lessee Operating Lease Liability Net Payments
LesseeOperatingLeaseLiabilityNetPayments
|
7644000 | |
CY2020Q4 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
185000 | |
CY2021Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
2500000 | |
CY2021Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
10000000 | |
CY2021Q3 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
7500000 | |
CY2021Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
20000000 | |
CY2021Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-136000 | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
665000 | ||
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
CY2020Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 |